Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOTRE: Optimizing LAI PrEP and MOUD in Carceral Settings
NCT06854029Phase 4Not yet recruiting
- Sponsor
- Duke University
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of cabotegravir, buprenorphine extended-release injection in human immunodeficiency virus infection (HIV), opioid use disorder (OUD), sponsored by Duke University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cabotegravirbuprenorphine extended-release injection
03
Conditions
human immunodeficiency virus infection (HIV)opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06854029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854029.